Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rachel M. A. Linger"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/6cb8ae1da41e406aab010f40dd28241a
Autor:
Justine Migdall-Wilson, Christine Bates, Jennifer Schlegel, Luis Brandão, Rachel M A Linger, Deborah DeRyckere, Douglas K Graham
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31635 (2012)
Mer tyrosine kinase is ectopically expressed in acute lymphoblastic leukemia and associated with enhanced chemoresistance and disease progression. While such effects are generally ascribed to increased engagement of oncogenic pathways downstream of M
Externí odkaz:
https://doaj.org/article/b042023cc7a545babf40f687625a3be1
Autor:
Jacquelyn D Waller, Rachel M. A. Linger, Keaton Maguire, Tesia C. Kolodziejczyk, Colby L. Presley
Publikováno v:
The FASEB Journal. 34:1-1
Autor:
Kristen M. Jacobsen, Kelly K. Sawczyn, Aik Choon Tan, Douglas K. Graham, Deborah DeRyckere, Rachel M. A. Linger, Xiayuan Liang, H. Shelton Earp, Luis Brandao, Amy K. Keating, Amanda Winges, Amy McGranahan, Alisa B. Lee-Sherick, Rebecca A. Cohen
Publikováno v:
Blood. 122:1599-1609
Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 85%. However, alterations to treatment strategies using available drugs are unlikely to provide significant improvement in surviv
Autor:
Daniel T. Merrick, Douglas K. Graham, Rachel M. A. Linger, Wilbur A. Franklin, Christopher T. Cummings, Deryck H.G. Middleton, Rebecca A. Cohen, Deborah DeRyckere, Xian Lu, Susan Sather, Lynn E. Heasley, Anna E. Barón, Paul Jedlicka, Justine Migdall-Wilson
Publikováno v:
Oncogene
Non-small cell lung cancer (NSCLC) is a prevalent and devastating disease that claims more lives than breast, prostate, colon and pancreatic cancers combined. Current research suggests that standard chemotherapy regimens have been optimized to maxima
Publikováno v:
British Journal of Haematology. 151:295-311
Modifications to the treatment of acute lymphoblastic leukaemia (ALL) in children have led to a dramatic increase in survival in the past 40 years. Despite this success, a significant subset of paediatric leukaemia patients either relapse or fail to
Autor:
Kelly K. Sawczyn, Amy K. Keating, Deborah DeRyckere, Rachel M. A. Linger, Douglas K. Graham, Kristen M. Jacobsen, Luis Brandao, Xiayuan Liang
Publikováno v:
Blood. 114:2678-2687
Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 80%. However, additional changes using available drugs are unlikely to provide significant improvement in survival. New therapies
Autor:
Rachel M. A. Linger, Deborah DeRyckere, Douglas K. Graham, Gregory Kirkpatrick, Kurtis D. Davies, Rebecca A. Cohen, Christopher T. Cummings, H. Shelton Earp, Susan Sather
Publikováno v:
Oncotarget
// Christopher T. Cummings 1,* , Rachel M.A. Linger 1,4,* , Rebecca A. Cohen 1 , Susan Sather 1 , Gregory D. Kirkpatrick 1 , Kurtis D. Davies 1 , Deborah DeRyckere 1 , H. Shelton Earp 2,3 and Douglas K. Graham 1 1 Department of Pediatrics, Section of
Autor:
Douglas K. Graham, Rachel M. A. Linger, Christine Bates, Jennifer Schlegel, Justine Migdall-Wilson, Deborah DeRyckere, Luis Brandao
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31635 (2012)
PLoS ONE
PLoS ONE
Mer tyrosine kinase is ectopically expressed in acute lymphoblastic leukemia and associated with enhanced chemoresistance and disease progression. While such effects are generally ascribed to increased engagement of oncogenic pathways downstream of M
Publikováno v:
Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Review on MERTK (c-mer proto-oncogene tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is implicated.